Insider Trading March 19, 2026

Kaltura Director Disposes of 93,624 Shares as Stock Nears 52-Week Low

Sale executed under 10b5-1 plan; company posted stronger-than-expected Q4 2025 results

By Leila Farooq KLTR
Kaltura Director Disposes of 93,624 Shares as Stock Nears 52-Week Low
KLTR

Kaltura INC director Naama Halevi-Davidov sold 93,624 shares on March 18, 2026 under a pre-established Rule 10b5-1 plan, realizing $112,685 at a weighted average price of $1.2036. The transaction occurred while the stock traded close to a 52-week low, even as the company reported quarterly results that beat EPS and revenue expectations.

Key Points

  • Director Naama Halevi-Davidov sold 93,624 Kaltura shares on March 18, 2026 at a weighted average price of $1.2036, totaling $112,685; sale prices ranged from $1.20 to $1.23.
  • The transaction was executed under a Rule 10b5-1 trading plan adopted December 16, 2025; after the sale the director directly owns 368,682 shares.
  • Kaltura reported Q4 2025 EPS of $0.03 versus an expected $0.0006 (a 4900% surprise) and revenue of $45.5 million versus an expected $45.32 million; analysts have not issued recent upgrades or downgrades.

Director Naama Halevi-Davidov reported the sale of 93,624 shares of Kaltura INC (NASDAQ:KLTR) common stock on March 18, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $1.2036, producing proceeds of $112,685. Reported sale prices ranged from $1.20 to $1.23.

The disposition occurred as Kaltura's share price sits near its 52-week low of $1.16. Over the most recent week, the stock declined 12.59% and was trading at $1.11 at the time of the report.

Following the sale, Halevi-Davidov's direct holdings in the company stand at 368,682 shares. The filing notes the transaction was carried out pursuant to a Rule 10b5-1 trading plan that the director adopted on December 16, 2025.


Quarterly results and market context

Separately, Kaltura reported its fourth-quarter 2025 financial results, posting earnings per share of $0.03 compared with an expected $0.0006 - a variance described in the filing as a 4900% surprise. Quarterly revenue was reported at $45.5 million, modestly above the $45.32 million analysts had forecast. The company framed the results as evidence of robust performance for the quarter.

The filing indicates that analysts have not recorded recent upgrades or downgrades for Kaltura. The company’s beat on both EPS and revenue may factor into future evaluations, but the document does not detail any immediate changes in analyst recommendations.


Investor considerations

  • Insider selling was executed under an existing 10b5-1 schedule, which typically sets predetermined parameters for transactions.
  • The sale took place against a backdrop of mixed signals: strong quarterly results on EPS and revenue, but a share price trading near its 52-week low and off over 12% in the prior week.
  • Following the transaction, the director remains a substantial shareholder with 368,682 shares directly owned.

Investors and market observers will likely weigh the company’s recent earnings surprise alongside the insider sale and current share price performance as they assess Kaltura's near-term outlook.

Risks

  • The company’s stock is trading near its 52-week low of $1.16 and fell 12.59% over the past week to $1.11, indicating downside pressure in the equity - this impacts equity investors and market sentiment.
  • Insider sales, even when executed under pre-set plans, can be perceived negatively by some market participants and may influence short-term trading dynamics in the stock.
  • While the quarter showed a strong EPS surprise and modest revenue beat, the filing notes no recent analyst rating changes, leaving uncertainty around how the results will translate into formal revisions of analyst outlooks.

More from Insider Trading

Glaukos Development Chief Sells $101K in Stock as FDA Clears Repeat Dosing for iDose TR Mar 19, 2026 Kestra Medical CEO Executes $304K Stock Sale, Company Posts Mixed Q3 Results Mar 19, 2026 Glaukos CFO Sells $61,968 in Stock as Company Moves Forward with iDose Readministration Approval Mar 19, 2026 QuickLogic Director Disposes $17,966 in Shares as Stock Trades Near Yearly High Mar 19, 2026 Twist Bioscience Director Executes $470,000 Stock Sale, Exercises Options Same Day Mar 19, 2026